These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25751382)

  • 1. [Clinical emergence features and implications of hepatitis B virus rtA181T mutation].
    Li X; Jiang L; Li F; Liu Y; Dai J; Zhao P; Qin Y; Li J; Xu D
    Zhonghua Gan Zang Bing Za Zhi; 2015 Jan; 23(1):23-7. PubMed ID: 25751382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
    Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
    Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
    J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
    Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological characteristics comparison of HBV rtA181T mutants with truncated or substituted HBsAg expression in vitro and in vivo model systems.
    Zhou LY; Chen EQ; Wang ML; Chen LL; Liu CP; Zeng F; Tang H
    Sci Rep; 2016 Dec; 6():39260. PubMed ID: 27976732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between hepatitis B virus reverse transcriptase 181 mutation and S gene mutation in hepatitis B virus chronically infected patients.
    Wang LP; Han FZ; Yan XB; Fan YC; Wang K
    Cell Mol Biol (Noisy-le-grand); 2016 Oct; 62(12):18-23. PubMed ID: 27894395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene.
    Ahn SH; Park YK; Park ES; Kim JH; Kim DH; Lim KH; Jang MS; Choe WH; Ko SY; Sung IK; Kwon SY; Kim KH
    J Virol; 2014 Jun; 88(12):6805-18. PubMed ID: 24696492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.
    Warner N; Locarnini S
    Hepatology; 2008 Jul; 48(1):88-98. PubMed ID: 18537180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B e antigen-suppressing mutations enhance the replication efficiency of adefovir-resistant hepatitis B virus strains.
    Herbers U; Amini-Bavil-Olyaee S; Mueller A; Luedde T; Trautwein C; Tacke F
    J Viral Hepat; 2013 Feb; 20(2):141-8. PubMed ID: 23301549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Possible Involvement of Multidrug-Resistant Hepatitis B Virus sW172* Truncation Variant in the ER Stress Signaling Pathway during Hepatocarcinogenesis.
    Zheng J; Jiang S; Lu F
    Jpn J Infect Dis; 2016 Jul; 69(4):306-13. PubMed ID: 26567840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
    Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
    J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological characteristics of the rtA181T/sW172* mutant strain of Hepatitis B virus in animal model.
    Dai J; Chen EQ; Bai L; Gong DY; Zhou QL; Cheng X; Huang FJ; Tang H
    Virol J; 2012 Nov; 9():280. PubMed ID: 23171829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of the rtA181T/sW172* mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B.
    Yeh CT; Chen T; Hsu CW; Chen YC; Lai MW; Liang KH; Chen TC
    BMC Cancer; 2011 Sep; 11():398. PubMed ID: 21933446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure.
    Villet S; Pichoud C; Billioud G; Barraud L; Durantel S; Trépo C; Zoulim F
    J Hepatol; 2008 May; 48(5):747-55. PubMed ID: 18331765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif.
    Yatsuji H; Noguchi C; Hiraga N; Mori N; Tsuge M; Imamura M; Takahashi S; Iwao E; Fujimoto Y; Ochi H; Abe H; Maekawa T; Tateno C; Yoshizato K; Suzuki F; Kumada H; Chayama K
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3867-74. PubMed ID: 16982790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.
    Villet S; Pichoud C; Villeneuve JP; Trépo C; Zoulim F
    Gastroenterology; 2006 Oct; 131(4):1253-61. PubMed ID: 17030194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.
    Lai MW; Yeh CT
    Antivir Ther; 2008; 13(7):875-9. PubMed ID: 19043921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.